Expanded US patent approval for DiviTum™

Biovica has received expanded patent approval for the DiviTum™ kit-technology by the United States Patent and Trademark office. The patent protection for DiviTum™ now includes both the method and kit. DiviTum™ has patent protection in the US & Canada and across Europe, in total 49 countries.
Biovica has developed DiviTum™, a non-invasive blood test, for the rapid and reliable evaluation of therapy efficacy in patients with advanced cancer. The first application of DiviTum™ is evaluation of the efficacy of specific treatments in advanced breast cancer. The aim is to give physicians more supporting data in order to optimize treatment outcome for patients. DiviTum™ has in several clinical studies demonstrated unique values in predicting patient outcome and therapy efficacy, as well as monitoring cancer treatment.

Biovica is currently expanding its clinical trial programs and is collaborating with several leading cancer institutes in Europe and the US. The ongoing study programs aim to further document the application of DiviTum™ in solid tumors.

Anders Rylander, CEO Biovica, comments: “This expanded approval strengthens our patent protection in the US. We will continue to document the unique value that DiviTum™ can bring to patients with cancer and a more optimal treatment outcome. Our goal is that DiviTum in the future will help physicians to faster evaluate therapy efficacy in order to better optimize their patients’ treatments.”


Biovica is a bio-diagnostic company focused on providing improved diagnostics, predictive data and monitoring of cancer patient under treatment. Biovica has developed DiviTum™, a highly sensitive assay for measuring cell proliferation. Since one of the most fundamental characteristics of cancer is uncontrolled and increased cell growth, DiviTum™ enables valuable prediction capability and monitoring of compounds regulating cell proliferation and the cell cycle. Biovica is ISO 13485 certified for Quality Management Systems and DiviTum™ is CE labeled and MPA registered.


Anders Rylander, CEO
Direct +46 (0) 18 44 44 835
E-mail anders.rylander@biovica.com


Swedish (PDF)

English (PDF)

2017-01-03T10:41:14+00:00 August 31st, 2016 09:00|Regulatory|